Health & Fitness
Health and FitnessHealth and Fitness 
Tue, February 15, 2011
Zynex Senior Executive Announces Retirement after 15 Years of Service
LONE TREE, Colo.--([ BUSINESS WIRE ])--Zynex, Inc. (OTCBB: [ ZYXI ]), a provider of pain management systems and electrotherapy products for medical patients with functional disability, announced the retirement of Birgitte Sandgaard, Vice President of Billing.
Mrs. Sandgaard helped start Zynex over 15 years ago and has been in charge of all billing and collection activities of the Company. Mrs. Sandgaard was responsible for establishing the Companya™s collection processes and procedures and played a primary role in the development and implementation of the Companya™s billing system, which is still in place today. Mrs. Sandgaard will remain as a consultant of the Company to assist with any transition or business related issues.
Thomas Sandgaard, CEO stated, aWe are grateful to Birgitte for her dedication, knowledge and experience she brought to Zynex. Her leadership and guidance have been felt in all areas of the organization. I believe that the processes, procedures and system she implemented in the billing department will benefit the Company for many years to come and ensure a smooth transition. We thank her for her service and wish her the best in retirement.a
About Zynex
Zynex, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of medical devices in three subsidiaries. Zynex Medical is a provider of electrotherapy products for home use, Zynex Monitoring Solutions develops products for cardiac monitoring for use in hospitals and Zynex NeuroDiagnostic develops devices for EMG and EEG diagnostic purposes in the neurology clinic markets. Zynex Medical's product line is fully developed, FDA-cleared, commercially sold, and has been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex Monitoring Solutions and Zynex NeuroDiagnostic are currently both in the development stages without any significant revenues. For additional information please visit: [ http://www.ir-site.com/zynex/default.asp ].
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third-party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the aRisk Factorsa section of our Annual Report on Form 10-K for the year ended December 31, 2009.